RedHill Biopharma Ltd.
corporate_fare Company Profile
RedHill Biopharma Ltd. (NASDAQ:RDHL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for RDHL at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- RedHill Biopharma in WHO Talks for Opaganib as Ebola Treatment Amid Outbreak
- RedHill Biopharma Expands ATM Offering by $1.59M, Totaling $1.85M, Signaling Significant Dilution Amidst Going Concern Warning
- RedHill's RHB-204 Shows Comparable Efficacy for Crohn's Disease, Pursues Non-Dilutive Funding
- RedHill Biopharma Reports Going Concern Doubt, Unremediated Material Weakness, and Nasdaq Delisting Risk in 2025 Annual Report
- RedHill Biopharma Reports FY2025 Results: Achieves Positive Equity, Secures Key Partnerships & $10.5M Court Win
Financial Snapshot
Insider Transactions
RDHL files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.